Penumbra, Inc.
PEN
NYSE·Healthcare·Medical - Devices·Mkt cap $12.6B
$321.00
▼ -0.63%
P/E
187.72
Mkt Cap
$12.6B
52-Wk Range
$221.26–$362.41
52-Week Range
$221.26 - $362.41
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 20.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
2 risks
- Low volatility (beta 0.7).
- Extreme premium - high expectations embedded
Growth
Strong growth ahead
Value
Extreme premium - high expectations embedded
Momentum
Stable
+0.2% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying PEN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
JUL 30, 2026
Reported EPS of $0.88 vs $1.16 consensus (-24.1% surprise). Revenue of $390.0M vs $389.6M expected (+0.1%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-24.1%
Revenue trend · last 2Q
—
+15%
Q1 26
Q2 26
$374.8M
$390.0M
Margins · last 2Q
Gross
67.9%
Operating
10.5%
Profit
8.9%
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: Evercore · Jul 6, 2026
vs Industry
How PEN stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.